Últimas noticias sobre Theriva Biologics (AMEX:TOVX) Bolsa

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMPG

AVGR

BIPC

CHEK

CREV

FDSB

HSDT

KORE

LAES

LIND

NCRA

NEUE

NVNI

RELI

SLGL

TIVC

TLRY

TOVX

Carbon Revolution lidera con un aumento del 62,4% en el premercado. ¿Qué otras acciones destacaron antes de la apertura?

Las acciones de Carbon Revolution (CREV) están subiendo un 62%; 20 acciones que se están moviendo en el premercado

Theriva Biologics Inc

JP Morgan analyst Joseph Cardoso maintains Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) with a Neutral and lowers the price target from $260 to $220.

Price Target

Analyst Ratings

GRMN

JP Morgan Maintains Neutral on Garmin, Lowers Price Target to $220

JP Morgan analyst Samik Chatterjee maintains Flex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) with a Overweight and lowers the price target from $52 to $40.

FLEX

JP Morgan Maintains Overweight on Flex, Lowers Price Target to $40

JP Morgan analyst Samik Chatterjee maintains Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) with a Neutral and lowers the price target from $265 to $220.

JP Morgan Maintains Neutral on Fabrinet, Lowers Price Target to $220

<a href="https://event.webcasts.com/starthere.jsp?ei=1711730&amp;tp_key=88606432f4">https://event.webcasts.com/starthere.jsp?ei=1711730&amp;tp_key=88606432f4</a>
&nbsp;

Guidance

Events

UnitedHealth Group CEO Reports Evidence Of Increase In Earlier Wellness Visits To Primary Care Physicians From Older Americans

Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44852132/costco-wholesale-corporation-announces-an-increase-in-its-quarterly-cash-dividend" rel="noreferrer noopener">increased its quarterly dividend</a> on Thursday, raising its regular cash payout from $1.16 to $1.30 per share. The proposed increment amounts to a 12% increase in the quarterly dividend.
The revised quarterly dividend will amount to $5.20 annually and is scheduled for distribution on May 16, 2025, to shareholders who hold Costco stock as of the close of business on May 2, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44850301/target-under-pressure-from-discretionary-spend-slowdown-mounting-inventory-risk-goldman-sachs-downgrades-stock" rel="noreferrer noopener">Target Under Pressure From Discretionary Spend Slowdown, Mounting Inventory Risk, Goldman Sachs Downgrades Stock</a>
Costco held <a target="_blank" href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0000909832/53d4ecad-8de9-4252-8ef7-9cf31eb7ac5a.pdf" rel="noreferrer noopener">$12.4 billion in cash and equivalents</a> as of February 16, 2025. Last week, the retailer reported March <a target="_blank" href="https://www.benzinga.com/25/04/44745979/costco-wholesale-posts-strong-march-sales-uptick-in-purchases-ahead-of-tariffs-analysts-say" rel="noreferrer noopener">same-store sales growth</a> of 9.1%, with the U.S. comparable sales of 8.7%.
As of now, Costco operates 904 warehouse locations around the world. The bulk of its operations, 623 stores are based in the United States and Puerto Rico.
The remainder are spread across markets like Canada, Mexico, Japan, the United Kingdom, South Korea, Australia, and several other countries.
Beyond its physical locations, Costco&#8217;s online storefronts serve consumers in major markets such as the U.S., Canada, the U.K., Mexico, Korea, Taiwan, Japan, and Australia.
Costco is due to report third-quarter earnings on May 29.
<h2 class="wp-block-heading">Costco Wholesale Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Costco Wholesale, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Costco Wholesale, the 200-day moving average sits at $924.32, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is below the current price of $967.75. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: COST shares closed higher by 0.65% at $974 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44850223/march-retail-sales-exceed-forecasts-says-analyst" target="_blank" rel="noreferrer noopener">March Retail Sales Exceed Forecasts, Analyst Notes Best-Performing Sectors</a></li>
</ul>
Photo by Steve Travelguide via Shutterstock

Dividends

General

COST

Retail Giant Costco Raises Dividend By 12%

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">195.95</td>
<td align="right">2.04</td>
<td align="right">1.05</td>
<td>115.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">80.47</td>
<td align="right">0.77</td>
<td align="right">0.96</td>
<td>42.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">185.84</td>
<td align="right">1.60</td>
<td align="right">0.86</td>
<td>4.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">90.17</td>
<td align="right">0.54</td>
<td align="right">0.60</td>
<td>554</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">125.27</td>
<td align="right">0.65</td>
<td align="right">0.52</td>
<td>18.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">80.51</td>
<td align="right">0.31</td>
<td align="right">0.38</td>
<td>6.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">39.97</td>
<td align="right">0.15</td>
<td align="right">0.37</td>
<td>505</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">46.67</td>
<td align="right">0.14</td>
<td align="right">0.30</td>
<td>354.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">77.10</td>
<td align="right">0.12</td>
<td align="right">0.15</td>
<td>2.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.27</td>
<td align="right">0.11</td>
<td align="right">0.13</td>
<td>1.7K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">135</td>
<td align="right">-1.29</td>
<td align="right">-0.95</td>
<td>46.5K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For April 17, 2025

JP Morgan analyst Samik Chatterjee maintains F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a Neutral and lowers the price target from $296 to $285.

FFIV

JP Morgan Maintains Neutral on F5, Lowers Price Target to $285

Avis Budget Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) shares jumped Wednesday, gaining 4.3% to $72.69 during regular trading and rising another 3.2% to $74.99 in after-hours trading. The move came as investors responded to news that billionaire investor Bill Ackman's Pershing Square Capital Management <a href="https://www.benzinga.com/25/04/44838080/hertz-global-stock-soars-after-pershing-square-hops-in-passenger-seat-whats-going-on">significantly increased its stake</a> in Hertz Global Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>).
What To Know: Ackman's firm revealed in a late filing that it had accumulated 12.71 million Hertz shares as of Dec. 31, or 4.1% ownership, but a CNBC report later revealed the <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44853443/hertz-stock-accelerates-into-the-close-shares-continue-to-move-higher-after-hours-heres-why">stake had quietly grown to 19.8%</a>, making Pershing Square the second-largest Hertz shareholder. Ackman reportedly secured a confidential treatment provision from the SEC, allowing him to delay disclosure while building the position.
While Avis and Hertz are direct competitors in the rental car space, if tariffs don't affect used cars (<a href="https://www.benzinga.com/trading-ideas/movers/25/04/44853443/hertz-stock-accelerates-into-the-close-shares-continue-to-move-higher-after-hours-heres-why">as is reportedly Ackman's thesis</a>), rental fleets could become a safer asset class, which could generally signal broader confidence in the car rental sector.
Rising used car prices or stabilization in that market also improves the value of rental fleets and boosts potential resale margins, a key revenue stream for companies like Hertz and Avis.
Avis shares are also heavily shorted—about 32.5% of shares, according to <a href="https://www.benzinga.com/pro/register?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=ZKf4B99POPEe">Benzinga Pro</a>. That means positive news, like Bill Ackman's large investment in Hertz, could spark a short squeeze and push the stock even higher.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44850992/stocks-sink-as-powell-dismisses-fed-put-safety-net-gold-extends-massive-lead-over-nasdaq">Stocks Sink As Powell Dismisses &#8216;Fed Put&#8217; Safety Net, Gold Extends Massive Lead Over Nasdaq</a>
<h2 class="wp-block-heading">How To Buy CAR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Avis Budget Group&#8217;s case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CAR has a 52-week high of $132.25 and a 52-week low of $54.03.

What's Going On With Avis Budget Group (CAR) Stock?

Stifel analyst Tore Svanberg maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy and lowers the price target from $150 to $100.

ALAB

Stifel Maintains Buy on Astera Labs, Lowers Price Target to $100

State Street Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) shares are trading lower on Thursday after the company <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">reported its first quarter results.</a>
The company reported <a target="_blank" href="https://s203.q4cdn.com/888565246/files/doc_financials/2025/q1/STT-1Q25-Earnings-Press-Release-vFinal.pdf" rel="noreferrer noopener">quarterly </a>earnings per share of $2.04, beating the analyst consensus estimate of $1.99.
Quarterly sales of $3.28 billion (+4.7% year over year) missed the street view of $3.32 billion.
&#8220;Through broad-based year-over-year fee revenue growth and continued expense discipline, we achieved positive fee and total operating leverage alongside healthy pre-tax margin expansion, all while continuing to return capital to our shareholders,&#8221; said State Street CEO Ron O&#8217;Hanley. 
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/04/44627824/state-streets-strategic-investment-in-ethic-aims-to-revolutionize-personalized-portfolios" rel="noreferrer noopener">State Street&#8217;s Strategic Investment in Ethic Aims to Revolutionize Personalized Portfolios</a>
Net interest income remained broadly flat year over year to $714 million, as higher investment security yields and continued loan growth were offset by lower average short-end rates and a deposit mix shift.
Provision for credit losses fell year-over-year to $12 million from $27 million in the year-ago period.
In the quarter under review, State Street returned a total of $320 million of capital to common shareholders, including $100 million of common share repurchases and $220 million (or 76 cents per share) of declared dividends.
Common equity tier 1 ratio at the end of first quarter was 11%, compared with 11.1% a year ago.
O'Hanley noted that investors and the global economy face heightened uncertainty driven by geopolitical tensions and shifting government policies on trade, deficits, taxation, and deregulation.
&#8220;State Street has a long-standing history of resilience and adaptability, which has seen us through many challenging operating environments and has equipped us to effectively support our clients,&#8221; he added.
Price Action: STT shares are trading lower by 1.81% to $78.19 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44860240/unitedhealth-slashes-2025-outlook-on-medicare-funding-reductions-stock-crashes" target="_blank" rel="noreferrer noopener">UnitedHealth Slashes 2025 Outlook On Medicare Funding Reductions, Stock Crashes</a></li>
</ul>
Image: Shutterstock

Earnings

Equities

State Street Tops EPS, Misses Revenue — CEO Cites Resilience Despite Global Uncertainty

JP Morgan analyst Samik Chatterjee maintains Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) with a Overweight and lowers the price target from $150 to $108.

DELL

JP Morgan Maintains Overweight on Dell Technologies, Lowers Price Target to $108

Stifel analyst Tore Svanberg maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy and lowers the price target from $275 to $225.

Stifel Maintains Buy on Analog Devices, Lowers Price Target to $225

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading near our pivot at 528.66. Bulls will first target a move upward towards 530.09, aiming to establish stability above this price. If buyers maintain control, expect further upward momentum towards 532.56. Sustained strength above this area could trigger additional upside, pushing towards 534.17. The highest bullish objective for today on SPY stands at 534.53.
Should 528.66 fail to offer support, bears will likely target a move down towards 526.31. Continued selling here might open the door to test lower levels around 525.26. If selling pressure intensifies below this threshold, expect the bears to press toward the significant support of 523.76. In the event of aggressive downside momentum today, the extreme bearish target is set at 521.85.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is currently trading near our critical price point at 447.73. For bullish momentum to prevail, traders must successfully hold prices above this mark, aiming initially for stability at 449.36. Persistent buying would then encourage bulls to target 450.98 next. Strong upside participation today could further propel prices to test 452.14. The maximum bullish objective for QQQ today is set at 454.10.
Conversely, if buyers fail to support 447.73 during the regular session, bears will attempt to drive prices down towards the 445.43 level. Weakness here could see a deeper decline to 444.09. Continued bearish activity would likely result in further downward pressure towards 442.53. A breakdown below this support might lead to today&#8217;s low-end bearish target of 440.78.
Apple Inc. (AAPL)
Apple is trading around our pivot area of 196.01. Bulls must defend this level to encourage upward momentum, initially targeting the 197.00 region. A successful bullish push could further lift prices to 197.69. Should buyers sustain strong momentum throughout today&#8217;s session, we anticipate a move towards our primary bullish objective of 198.79.
However, if the 196.01 level proves vulnerable, expect sellers to target an initial move down towards 195.25.&nbsp;
Continued weakness would prompt bears to seek lower prices at 194.40. An escalation in bearish activity could bring 193.95 into focus. If this support level deteriorates, sellers may aggressively push towards our daily bearish objective at 192.76.
Microsoft Corp. (MSFT)
Microsoft is presently trading around the important 373.48 level. Bulls are aiming for a strong upward advance towards 375.11 and need sustained buying to secure this as solid intraday support. Confirmed bullish strength above this level would likely drive prices upward toward 376.70. Extended buying strength today could propel Microsoft toward our upper bullish target at 380.59.
Conversely, a failure to sustain 373.48 as support would likely trigger bearish efforts to push the market lower towards 372.03. If selling becomes persistent below this point, anticipate additional downside pressure targeting 370.10. Further bearish momentum could drag prices down towards 368.79. A pronounced sell-off scenario today places our ultimate bearish target for Microsoft at 366.98.
NVIDIA Corporation (NVDA)
NVIDIA is currently trading around our notable pivot level at 105.23. Bullish traders aim for an upward move to establish 106.30 as firm intraday support. If buying continues actively, expect bulls to drive prices higher towards the next significant resistance at 107.51. Continued bullish momentum could subsequently propel prices toward 109.12, with our maximum bullish target on NVIDIA today set at 112.54.
If 105.23 does not hold as effective support, bears will initially target a downward move towards 103.96. Persistent selling below this mark could trigger a deeper bearish push towards 102.55. Weak price action today might encourage bears to test further support at 101.02. Should sellers maintain strong downside pressure, NVIDIA may extend its decline toward our lowest bearish target of 99.87.
Alphabet Inc Class A (GOOGL)
Alphabet is presently trading near our pivotal level of 154.95. Bulls must secure prices above this area to facilitate an advance towards 155.59. Continued bullish engagement would enable a sustained upward move towards our primary bullish target today of 157.41.
If sellers overwhelm 154.95 during regular trading, expect the bears to target lower prices around 153.93 initially. Further weakening below this level would likely push prices toward the 152.27 mark. Strong bearish activity could drive Alphabet to today&#8217;s ultimate downside target at 151.24.
Meta Platforms Inc (META)
Meta is currently fluctuating around our key pivot at 504.54. Bulls must strongly support this level to initiate an upward advance towards the critical area of 512.85. Persistent bullish strength would potentially see the market extend higher toward 520.27. A continuation of bullish sentiment today could ultimately lift prices towards our highest bullish objective at 526.29.
If 504.54 support is breached during today&#8217;s session, sellers will target a downward move towards the 500.83 level. Extended bearish momentum may result in prices declining further to test 498.03. A continued breakdown could see Meta retreating towards today&#8217;s lowest bearish target at 495.54.
Tesla Inc. (TSLA)
Tesla is trading around the crucial pivot level of 242.49. Bullish participants need an initial push upwards toward 243.98. Continued buying enthusiasm might then propel the price action upward towards the next resistance at 246.16. An environment of broader market strength could further extend Tesla&#8217;s rally to test higher at 248.37. If bullish momentum intensifies today, anticipate reaching our top bullish target at 250.25.
Should Tesla fail to maintain support at 242.49, bears will first aim to push the market downwards towards 239.92. Persistent selling here could lead to further downside activity at 238.50. If bearish participation remains active, sellers will target an aggressive move downward to today&#8217;s most extreme bearish objective at 235.74.
Final Word:&nbsp;
Today marks the end of this abbreviated trading week, as markets will observe the Good Friday holiday tomorrow. Key economic indicators for release include Housing Starts and Preliminary Building Permits for March, accompanied by the Philly Fed Business Outlook report for April. However, traders will particularly focus on the Initial and Continuing Jobless Claims data, which could significantly influence market sentiment, especially regarding expectations for future Fed actions. Additionally, at 11:45 AM ET, Federal Reserve&#8217;s Michael Barr, a current voting member, is scheduled to speak, potentially offering insights into monetary policy direction. 
Finally, traders should be aware of today&#8217;s 1:00 PM ET 5-Year TIPS auction hosted by the Treasury, adding another element of volatility. Crucially, today&#8217;s trading also coincides with Monthly Options Expiration (MOPEX), likely amplifying volatility levels due to market closure tomorrow. Exercise caution, adhere strictly to your risk management guidelines, and enjoy a relaxing three-day weekend!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

AAPL

How To Trade SPY And Top Tech Stocks, As March Housing Starts Fall 11.4%

Shares of Hooker Furnishings Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFT#NASDAQ">HOFT</a>) were <a href="https://www.benzinga.com/premarket">trading lower in premarket </a>on Thursday after the fourth-quarter FY25 earnings.
The company reported <a href="https://www.benzinga.com/pressreleases/25/04/g44858894/hooker-furnishings-reports-improved-sales-in-fourth-quarter-additional-planned-cost-savings">fourth-quarter FY25 sales growth of 8%</a> year-on-year to $104.46 million, beating the analyst consensus estimate of $101.16 million.
The additional week in the current period drove the increase, contributing approximately $7.7 million to consolidated net sales.
Segment Revenue: Hooker Branded segment sales climbed 31%, Home Meridian improved 21.7%, and Domestic Upholstery decreased 7%.
EPS of $(0.22) <a href="https://www.benzinga.com/earnings">missed the consensus</a> estimate of $0.16.
Gross margin contracted by 60 basis points Y/Y to 23.9%. Selling and administrative expenses increased 12% Y/Y to $25.2 million. The company reported an operating loss of $2.7 million in the quarter compared to an operating income of $340,000.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44850301/target-under-pressure-from-discretionary-spend-slowdown-mounting-inventory-risk-goldman-sachs-downgrades-stock">Target Under Pressure From Discretionary Spend Slowdown, Mounting Inventory Risk, Goldman Sachs Downgrades Stock</a>
The company held $6.3 million in cash and equivalents as of February 2. Net cash used in operating activities for FY25 totaled $23 million.
Cost Savings: Hooker expects fiscal 2026 cost savings, net of associated transition costs, of at least between $0.8 to $1.0 million from the Savannah warehouse exit announced in March 2025.
In addition to the $10 million in annualized cost savings announced in fiscal 2025, the company expects additional annualized cost savings of between $8 to $10 million.
Total annualized savings of these two cost-saving plans which will be realized in FY27 is $18 million &#8211; $20 million.
&#8220;While macroeconomic headwinds—including a weak housing market, lower consumer confidence and tariff uncertainty—persist, we remain focused on what we can control. We&#8217;ve accelerated cost reduction initiatives which we believe will improve operating income and cash flow,&#8221; said CEO Jeremy R. Hoff.
&#8220;We are currently evaluating a range of strategies to mitigate the current economic environment, including a 50-year low in existing home sales, and the possible impact of additional reciprocal tariffs on our operations and profitability. Tariffs add tremendous complexity and uncertainty that require us to look at our cost structure more aggressively, particularly on the lower margin, direct container side of our business.&#8221;
Price Action: HOFT shares traded lower by 0.92% at $7.5 in premarket at last check Thursday.
Read Next: <a href="https://www.benzinga.com/25/04/44850223/march-retail-sales-exceed-forecasts-says-analyst">March Retail Sales Exceed Forecasts, Analyst Notes Best-Performing Sectors</a>
Photo: Shutterstock<a href="https://www.benzinga.com/go/plus500-futures" target="_blank" rel="noreferrer noopener"></a>
<a href="https://www.benzinga.com/go/plus500-futures" rel="noreferrer noopener" target="_blank"></a>

HOFT

What's Going On With Furniture Company Hooker Furnishings Stock Today?

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines">PRIME</a> program for novel medicines targeting unmet medical needs and the FDA's <a href="https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/fact-sheet-breakthrough-therapies">Breakthrough Therapies</a> program
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 17, 2025 / <a href="https://pr.report/8vx8">Jaguar Health, Inc.</a> <a href="https://pr.report/8vx9">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/8vxa">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/8vxb">Napo Therapeutics</a> today announced that preliminary results from the ongoing pediatric investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for various congenital diarrheal disorders (CDD), including MVID and SBS with intestinal failure (SBS-IF), will be presented by Dr. Mohamad Miqdady at the April 24-26, 2025 <a href="https://pr.report/8vxc">Annual ELITE PED-GI Congress</a> in Abu Dhabi in the United Arab Emirates.
MVID and SBS-IF, rare orphan diseases requiring intensive parenteral nutrition and support, have severe morbidity and mortality implications and impact the quality of life of both patients and their caregivers. There are currently no approved drug treatments for MVID. A key value driver would be a reduction in total parenteral nutrition (TPN).
"Patients with MVID and SBS-IF suffer from devastating diarrhea and dehydration caused by these debilitating, lifelong conditions. These patients are frequently on TPN for as long as 20 hours a day, seven days a week - and TPN carries a significant risk of morbidity, including infections, metabolic complications, and liver problems," said Dr. Miqdady, the principal investigator for this study. "I look forward to presenting preliminary, proof-of-concept results from this study at the ELITE PED-GI Congress."
This ongoing proof-of-concept study is evaluating crofelemer's potential to be safely administered to patients with MVID, SBS-IF, and other CDDs in escalating doses, improve stool formation, improve the absorption of nutrients, and lower TPN needs - which have never been achieved in an MVID patient. The study also provides the opportunity to evaluate whether any potential benefit provided by crofelemer in participating patients ceases after treatment with crofelemer is discontinued.

Biotech

JAGX

Jaguar Health Announces Preliminary Results From Ongoing Pediatric Investigator-Initiated Trial Of A Novel Liquid Formulation Of Crofelemer Will Be Presented By Dr. Mohamad Miqdady At April 24-26, 2025 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates

Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), a leader in innovative memory and storage solutions, today announced a market segment-based reorganization of its business units to capitalize on the transformative growth driven by AI, from data centers to edge devices.
Micron has maintained multiple generations of industry leadership in DRAM and NAND technology and has the strongest competitive positioning in its history. Micron's industry-leading product portfolio, combined with world-class manufacturing execution enables the development of differentiated solutions for its customers across end markets. As high-performance memory and storage become increasingly vital to drive the growth of AI, this Business Unit reorganization will allow Micron to stay at the forefront of innovation in each market segment through deeper customer engagement to address the dynamic needs of the industry.
Micron will begin transitioning to this new business structure immediately. The transition will be complete early in the company's fiscal fourth quarter, which begins on May 30, 2025. Micron will report financial results under the new business structure starting with the fourth quarter of fiscal year 2025. The four business units will be:
<ul>
<li>Cloud Memory Business Unit (CMBU): Focused on memory solutions for large hyperscale cloud customers, and high-bandwidth memory (HBM) for all data center customers. Raj Narasimhan, Senior Vice President and General Manager, who has led the Compute and Networking Business Unit (CNBU), will lead CMBU.</li>
<li>Core Data Center Business Unit (CDBU): Focused on memory solutions for OEM data center customers and storage solutions for all data center customers. Jeremy Werner, Senior Vice President and General Manager, who has led the Storage Business Unit (SBU), will lead CDBU.</li>
<li>Mobile and Client Business Unit (MCBU): Focused on memory and storage solutions for mobile and client segments. Mark Montierth, Corporate Vice President and General Manager, who has led the Mobile Business Unit (MBU), will lead MCBU.</li>
<li>Automotive and Embedded Business Unit (AEBU): Focused on memory and storage solutions for the automotive, industrial and consumer segments. Kris Baxter, Corporate Vice President and General Manager, who has led the Embedded Business Unit (EBU), will lead AEBU.</li>
</ul>
All four business units will continue to report to Sumit Sadana, Executive Vice President and Chief Business Officer.

Management

Micron Technology To Complete Business Reorganization By Early Fiscal Q4 2025; To Form 4 New Business Units; Raj Narasimhan To Lead Cloud Memory Business Unit; Jeremy Werner To Lead Core Data Center Business Unit

JP Morgan analyst Samik Chatterjee maintains Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) with a Overweight and lowers the price target from $62 to $50.

JP Morgan Maintains Overweight on Corning, Lowers Price Target to $50

Sadot Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) ("Sadot Group", "Sadot", or the "Company"), an emerging player in the global agri-food supply chain, is proud to announce that its newly established subsidiary, Sadot Korea, has successfully executed its first international commodity trades. These initial transactions involved sourcing food products from Australia and Indonesia, with final delivery to key markets in Kenya and other countries.
The launch of Sadot Korea, announced on March 26, 2025, represents a major milestone in the Company's strategy to expand its footprint in Northeast Asia. Leveraging South Korea's robust logistics and trade infrastructure, Sadot aims to establish the country as a hub for global agri-trade activity.

SDOT

Sadot Group Inc Announces First Commodity Trades Through New South Korea Subsidiary

Stifel analyst Rick Wise maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $135 to $145.

Stifel Maintains Buy on Abbott Laboratories, Raises Price Target to $145

TYSONS, Va. and INDIANAPOLIS, April 17, 2025 (GLOBE NEWSWIRE) -- The Indiana Fever and WTHR, the TEGNA owned NBC affiliate in Indianapolis, today announced a multi-year extension of their landmark distribution agreement to deliver more exciting basketball action to central Indiana fans than ever before.
WTHR and WALV, TEGNA's MeTV affiliate, will air 18 games locally, giving fans across central Indiana unprecedented access to watch the Fever in action as they fight for a return to the WNBA playoffs. Last season, WTHR's coverage elevated Indiana Fever viewership to new heights as the team's local broadcast home, broadening the fan base beyond hardcore sports enthusiasts. Fever games on WTHR were watched in nearly two-thirds more homes than nationally televised matchups, boasting a 63% household ratings increase over national network games.

TGNA

Indiana Fever And WTHR Announce Multi-year Extension Of Distribution Agreement To Deliver More Exciting Basketball Action To Central Indiana Fans

Press Releases

Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Health Care

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Aditxt

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Organovo Holdings

Palisade Bio

Plus Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Sunshine Biopharma

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Xenetic Biosciences

Maxim Group

Screenshot 2024-08-23 at 5.34.20 PM

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Comments

Theriva Biologics

Noticias

Últimas noticias sobre Theriva Biologics (AMEX:TOVX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL